PMID- 23651221
OWN - NLM
STAT- MEDLINE
DCOM- 20140325
LR  - 20151119
IS  - 1360-0443 (Electronic)
IS  - 0965-2140 (Linking)
VI  - 108
IP  - 9
DP  - 2013 Sep
TI  - 'Ecstasy' and the use of sleep medications in a general community sample: a 
      4-year follow-up.
PG  - 1640-8
LID - 10.1111/add.12200 [doi]
AB  - AIMS: Animal models show that a single dose of 3,4-methylenedioxymethamhetamine 
      (MDMA; 'ecstasy') can result in long-term disruption of sleep. We evaluated the 
      relationship between ecstasy consumption and the use of sleep medications in 
      humans after controlling for key factors. DESIGN: The Personality and Total 
      Health Through Life project uses a longitudinal cohort with follow-up every 4 
      years. This study reports data from waves 2 and 3. SETTING: Participants were 
      recruited from the electoral roll in the Australian Capital Territory and 
      Queanbeyan, New South Wales, Australia. PARTICIPANTS: Participants were aged 
      20-24 years at wave 1 (1999-2000). MEASURES: The study collected self-reported 
      data on ecstasy, meth/amphetamine, cannabis, alcohol, tobacco and use of sleeping 
      medications (pharmaceutical or other substances). Depression was categorized 
      using the Brief Patient Health Questionnaire (BPHQ). Other psychosocial measures 
      included life-time traumas. We used generalized estimating equations to model 
      outcomes. FINDINGS: Ecstasy data were available from 2128 people at wave 2 and 
      1977 at wave 3: sleeping medication use was reported by 227 (10.7%) respondents 
      at wave 2 and 239 (12.1%) at wave 3. Increased odds ratios (OR) for sleeping 
      medication use was found for those with depression [OR = 1.88, 95% confidence 
      interval (CI): 1.39, 2.53], women (OR = 1.44, 95% CI: 1.13, 1.84), and increased 
      by 19% for each life-time trauma. Ecstasy use was not a significant predictor, 
      but >/=monthly versus never meth/amphetamine use increased the odds (OR = 3.03, 95% 
      CI 1.30, 7.03). CONCLUSION: The use of ecstasy appears to be associated with the 
      use of sleeping medications but this association can be accounted for by other 
      factors.
CI  - (c) 2013 Society for the Study of Addiction.
FAU - Tait, Robert J
AU  - Tait RJ
AD  - Centre for Mental Health Research, Australian National University, Canberra, ACT, 
      Australia. robert.tait@curtin.edu.au
FAU - George, Amanda
AU  - George A
FAU - Olesen, Sarah
AU  - Olesen S
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20130507
PL  - England
TA  - Addiction
JT  - Addiction (Abingdon, England)
JID - 9304118
RN  - 0 (Hallucinogens)
RN  - 0 (Hypnotics and Sedatives)
RN  - KE1SEN21RM (N-Methyl-3,4-methylenedioxyamphetamine)
SB  - IM
MH  - Adult
MH  - Amphetamine-Related Disorders/*complications
MH  - Australian Capital Territory
MH  - Female
MH  - Follow-Up Studies
MH  - Hallucinogens/*adverse effects
MH  - Humans
MH  - Hypnotics and Sedatives/*therapeutic use
MH  - Male
MH  - N-Methyl-3,4-methylenedioxyamphetamine/*adverse effects
MH  - New South Wales
MH  - Sleep Wake Disorders/*chemically induced/drug therapy
MH  - Young Adult
OTO - NOTNLM
OT  - 3,4-Methylenedioxymethamphetamine (MDMA)
OT  - cohort
OT  - ecstasy
OT  - general community sample
OT  - longitudinal
OT  - meth/amphetamine
EDAT- 2013/05/09 06:00
MHDA- 2014/03/26 06:00
CRDT- 2013/05/09 06:00
PHST- 2012/10/09 00:00 [received]
PHST- 2012/12/17 00:00 [revised]
PHST- 2013/03/21 00:00 [accepted]
PHST- 2013/05/09 06:00 [entrez]
PHST- 2013/05/09 06:00 [pubmed]
PHST- 2014/03/26 06:00 [medline]
AID - 10.1111/add.12200 [doi]
PST - ppublish
SO  - Addiction. 2013 Sep;108(9):1640-8. doi: 10.1111/add.12200. Epub 2013 May 7.